Determining the safety, effects, and efficacy of Novus-CV in homoeopathic dilution in humans for Covid-19 disease prevention

ABSTRACT
Introduction
Homoeopathic philosophy suggests nosodes can be used before, during, and after active cases for prevention and treatment. The human immunological response to severe acute respiratory syndrome Covid-19 disease expression can range from mild symptoms leading to resolution, to severe symptoms leading to complete system collapse, death, or prolonged post-disease conditions. The target of any disease prevention program starts with supporting immune system responses and reducing susceptibility. Homoeoprophylaxis (HP) with the Novus-CV nosode, aims to activate mild, disease specific, short-lived immune responses intended to facilitate the disease process and/or lessen the effects of, or susceptibility to, Covid-19 disease expression. The mild, shortlived immunological responses to the nosode are considered an important step in preventing disease. The collated nosode driven symptom presentation of new and/or resolved symptoms can serve as a reference guide to the homoeopathic indications for use of the nosode in active or unresolved cases.

Method

Registration started March 13, 2020, prior to the initial peak of cases in the United State. Registrants undertook a self-administered dosing schedule of Novus-CV in various potencies. To establish safety, effects and efficacy of Novus-CV registrants of all age groups, from pregnant women and children to the elderly, registered a completed initial health profile, a two-week follow-up and a three-month follow-up. 

i. Safety was determined by assessing the types, duration, and degree of responses noted from the respondent. Also, by resultant changes, if any, in chronic health conditions. 

ii. Effects were overseen by registrants’ personal HP Supervisors and self-reported in online follow-up forms, and through verbal confirmation. These effects were considered proving and clinically curative effects and were collated by location, sensation, modalities, and extensions as per homoeopathic Materia Medica criteria. 

iii. Efficacy was evaluated for all respondents and specifically in those with definite exposure to either previous disease expression or active cases. 

Results

A total of 1169 people of all age groups registered in the study. Of these 846 responded to follow-up. Peak dosing dates took place prior to the spring surge in cases. A total of 3181 administered doses were reported from 796 respondents during the two-week follow-up period. A total of 2741 symptoms and/or change in symptoms were reported in all organ systems. Of the 89 respondents with previous disease expression, of which 17 were unresolved, 16.5 recovered after nosode administration. Of the 62 respondents with active disease expression upon registration, there was a 96.77% resolution rate. Of the 135 with known exposure to individuals with previous or active disease, 56 developed short-lived mild proving symptoms of which 98.7% resolved by the end of the dosing period, none developed Covid-19-like disease. Of the total 434 three-month respondents zero developed Covid-19- like disease during the follow-up period indicating that the HP dosing was 100% effective in disease prevention. After dosing, 0.02% of individuals experienced aggravation of chronic conditions suggesting minimal long-term negative effects.   Not a single adverse event was reported. Sixty-eight of the 434 three-month follow-ups reported single or multiple PCR or antibody tests all had negative results. The catalogued Materia Medica demonstrated sustained evolution from active disease to resolution and fear and sickness to confidence and well-being through the follow-up period.

Conclusions: Regardless of age of participant or previous health condition, the Novus-CV nosode can be used before, during, or after demonstration of Covid-19 symptom expression, to prevent disease, mitigate active disease and resolve past disease. With no associated adverse events reported, these results suggest Novus-CV nosode offers the world a low-risk disease prevention method that is 100% effective in those with definite exposure that deserves consideration in public health programs. Covid-19-like disease’ is the term we are using for the compilation of symptoms registrants had or developed during the study period. As no comprehensive testing or official diagnosis process was undertaken, subjective reports of the registrants and respondents was used to evaluate if they had a symptom expression consistent with the CDC description of the disease. Adverse events as defined by the National Institute of Health guidelines for research on human subject is defined as a death, life-threatening adverse drug or device experience, inpatient hospitalisation or prolongation of existing hospitalisation, a persistent disability/incapacity, or a congenital anomaly/birth defect. Throughout the research the tenets of homoeopathy were verified. The symptoms produced and resolved after dosing corresponded with the active disease presentation and ranged from short-lived, mild fevers, cough, vomiting and diarrhea, and general malaise to feelings of well-being and increased vitality; activation of acute discharges and fevers brought forth wellbeing. This catalogued Materia Medica can be used as the indications for effective clinical prescribing; it also offers insight into the nature of susceptibility of Covid-19 as we evolve through this epidemic, the homoeopathic principles of like cures like and acute disease resolves chronic disease, and it supports the concept that the miasmatic root of disease may be accountable for contagion. Accordingly, with the positive health effects noted in those with active or unresolved disease, Novus-CV is effective to treat or as an adjunct to treatment in active and unresolved cases. 

Reference: Birch, K., et al. "Determining the safety, effects, and efficacy of Novus-CV in homoeopathic dilution in humans for Covid-19 disease prevention." The Australian Journal of Homoeopathic Medicine 34.5 (2021): 1.

Full text link: http://3.144.248.189/files/similia-june-2021-article-kate-birch-et-al.pdf

No comments:

Post a Comment